AMBIEN Drug Patent Profile

When do Ambien patents expire, and what generic alternatives are available?

Ambien is a drug marketed by Cosette and is included in two NDAs.

The generic ingredient in AMBIEN is zolpidem tartrate. There are thirty-three drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the zolpidem tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ambien

A generic version of AMBIEN was approved as zolpidem tartrate by ACME LABS on April 23^rd, 2007.

Summary for AMBIEN

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	49
Patent Applications:	4,975
Drug Prices:	Drug price information for AMBIEN
Drug Sales Revenues:	Drug sales revenues for AMBIEN
What excipients (inactive ingredients) are in AMBIEN?	AMBIEN excipients list
DailyMed Link:	AMBIEN at DailyMed

See drug prices for AMBIEN

See drug sales revenues for AMBIEN

Recent Clinical Trials for AMBIEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institutes of Health (NIH)	Phase 2
University of Virginia	Phase 4
Patient-Centered Outcomes Research Institute	Phase 4

See all AMBIEN clinical trials

Pharmacology for AMBIEN

Drug Class	gamma-Aminobutyric Acid A Receptor Positive Modulator
Mechanism of Action	GABA A Receptor Positive Modulators
Physiological Effect	Central Nervous System Depression

US Patents and Regulatory Information for AMBIEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette	AMBIEN	zolpidem tartrate	TABLET;ORAL	019908-001	Dec 16, 1992	AB	RX	Yes	No
Cosette	AMBIEN CR	zolpidem tartrate	TABLET, EXTENDED RELEASE;ORAL	021774-001	Sep 2, 2005	AB	RX	Yes	Yes
Cosette	AMBIEN	zolpidem tartrate	TABLET;ORAL	019908-002	Dec 16, 1992	AB	RX	Yes	Yes
Cosette	AMBIEN CR	zolpidem tartrate	TABLET, EXTENDED RELEASE;ORAL	021774-002	Sep 2, 2005	AB	RX	Yes	No

Expired US Patents for AMBIEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cosette	AMBIEN	zolpidem tartrate	TABLET;ORAL	019908-001	Dec 16, 1992	4,382,938*PED
Cosette	AMBIEN	zolpidem tartrate	TABLET;ORAL	019908-002	Dec 16, 1992	4,382,938*PED

International Patents for AMBIEN

See the table below for patents covering AMBIEN around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	64091
African Intellectual Property Organization (OAPI)	7076
Denmark	465181
South Africa	8107297

Supplementary Protection Certificates for AMBIEN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2236132	C300714	Netherlands		PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
2236132	122015000006	Germany		PRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718
2236132	300714	Netherlands		PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 108438 - 439 20160624; REGISTRATION NO/DATE: BE424286 20120718 BE424295 20120718
2236132	CA 2015 00004	Denmark		PRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718

Market Dynamics and Financial Trajectory for Ambien (Zolpidem)

Last updated: February 20, 2026

What Are the Current Market Dynamics for Ambien?

Ambien (zolpidem), a sedative-hypnotic used for short-term treatment of insomnia, has experienced significant shifts in market share and competitive landscape over the past decade. Its market is characterized by high prevalence of insomnia, evolving regulatory guidelines, and competition from newer agents.

Market Size and Prevalence

• The global insomnia treatment market was valued at approximately $8.8 billion in 2021, with Ambien historically accounting for a significant portion (around 25%) of this segment [1].
• US adult insomnia prevalence is estimated at 10-15%, translating to over 30 million potential patients [2].

Patent Status and Generic Competition

• Original patent for Ambien (zolpidem) expired in 2015 in the US, enabling generic manufacturing.
• Generic versions now dominate prescriptions, reducing brand-market share.
• Brand sales peaked around $1.6 billion annually in the US in 2012; current sales are around $300-400 million, primarily from branded formulations and specialized markets [3].

Regulatory and Prescriber Market Trends

• The FDA updated labeling in 2013 to include warnings about complex sleep behaviors and potential dependency.
• Physicians shifted toward prescribing other agents like eszopiclone, suvorexant, and off-label use of melatonin, impacting Ambien's market share.
• Usage declined approximately 20% post-2013 but stabilized with newer formulations and extended-release versions.

Competitive Landscape

• Generics account for 80-90% of prescriptions.
• Newer drugs (e.g., Lunesta, Belsomra) offer alternative mechanisms of action with differing side effect profiles.
• OTC and non-pharmacological options have gained popularity, especially for mild insomnia.

What Is the Financial Trajectory for Ambien?

Revenue Trends

Year	US Brand Sales (USD millions)	Market Share	Notes
2012	1,602	~25%	Peak revenues
2015	800	~10%	Patent expiry; generics introduced
2018	500	~7%	Continued decline
2022	350	~5%	Market stabilization

• The decline resulted mainly from generic erosion and regulatory-driven prescriber shifts.

Profitability and R&D Investment

• The US-specific revenue after generic entry has made it less lucrative for the original manufacturer, Sanofi.
• R&D investments post-2015 shifted toward next-generation sleep agents and formulations, with limited investment directly into zolpidem.
• Margins on branded Ambien are below 20%, with generics operating at margins of 30-40% but with lower net revenues due to volume decline.

Future Outlook

• The overall insomnia pharmacotherapy market is projected to grow at CAGR 3-4% through 2030, driven by aging populations and increasing insomnia awareness [4].
• Ambien's market share is expected to decline further as generics dominate and newer drugs gain approval with unique benefits.
• Slight resurgence possible through product differentiation such as controlled-release formulations or combination therapies but unlikely to return to peak revenues.

What Are Key Factors Impacting Ambien’s Financial Trajectory?

• Regulatory changes focusing on dependency and adverse effects.
• Patent expirations, leading to generic proliferation.
• Development of alternatives with better safety profiles.
• Increasing preference for non-pharmacological treatments like cognitive-behavioral therapy for insomnia (CBT-I).

Key Takeaways

• Ambien's revenue declined from peak levels of over $1.6 billion to current figures below $400 million in the US.
• Patent expiry in 2015 accelerated generic competition, sharply reducing brand sales.
• Market growth for insomnia treatments favors newer drugs and non-drug interventions, hindering Ambien's recovery.
• The future relies heavily on formulations and marketing strategies that differentiate from generics.
• Investment in zolpidem-focused R&D is limited; growth prospects depend on external trends in healthcare and regulation.

FAQs

1. Is Ambien still a major player in the insomnia market?
No. Its market share has decreased significantly post-generic entry, with sales primarily from branded formulations in niche segments.

2. How does generic competition impact Ambien’s profitability?
Generics suppress premium pricing, reducing revenue and margins for the original branded product, leading to a revenue decline of approximately 75% since 2012.

3. Are there ongoing patent protections for Ambien?
No. The original patent expired in 2015, allowing generics to enter the market.

4. What are the primary alternatives to Ambien?
Eszopiclone (Lunesta), suvorexant (Belsomra), and off-label use of melatonin supplements.

5. What is the outlook for new formulations of zolpidem?
Limited. Most development focuses on extended-release versions or combination therapies, with no major new formulations expected to significantly alter current market dynamics.

References

1. MarketsandMarkets. (2022). Insomnia Market by Drug Type and Region. [Report]
2. CDC. (2020). Prevalence of Insomnia in U.S. Adults. [Data]
3. IQVIA. (2022). U.S. Prescription Drug Sales Data.
4. Grand View Research. (2021). Insomnia Market Size and Forecast.